Journal: Drugs in Context

Article Title: The journey of remdesivir: from Ebola to COVID-19

doi: 10.7573/dic.2020-4-14

Figure Lengend Snippet: Ongoing randomized trials for remdesivir registered on ClinicalTrials.gov .

Article Snippet: NCT04292899 , Randomized, open-label trial , Severe COVID-19 (SpO2 ≤ 94% or requiring supplemental oxygen). Cannot be intubated at screening or have CrCl < 50 mL/min; Multiple countries worldwide , Remdesivir for 5 days versus 10 days , Odds ratio for improvement , Recruiting.

Techniques:

Journal: Drugs

Article Title: Disease-Modifying Therapies in Type 1 Diabetes: A Look into the Future of Diabetes Practice

doi: 10.1007/s40265-018-1035-y

Figure Lengend Snippet: Selected immunotherapy studies in Stage 1 or Stage 2 TID

Article Snippet: Some of these studies are highlighted in . table ft1 table-wrap mode="anchored" t5 caption a7 Study agent, therapeutic mechanism Study name, references Study population Intervention Results Abatacept, (CTLA4-Ig), T-cell co-stimulation blockade CTLA4-Ig (Abatacept) for Prevention of Abnormal Glucose Tolerance and Diabetes in Relative At Risk for Type 1 Diabetes [ 91 ] TID relatives; stage 1; identified through TrialNet Pathway to Prevention; age 6–45;n=180 14 infusions of abatacept or placebo over 1 year Enrolling, study outcome expected 2020 Intranasal insulin/antigen therapy, mucosal tolerance Trial of Intranasal Insulin in Children and Young Adults at Risk of Type 1 Diabetes (INITII) [ 141 ] TID relatives; Stage 1; age 4–30; n=110; Nasal insulin or placebo; 440 iu daily × 7d then one day/week × 12 months Estimated completion 2019 Alum-GAD (Diamyd) and Vitamin D3/antigen therapy, tolerance Prevention Trial: Immune- tolerance With Alum-GAD (Diamyd) and Vitamin D3 to Children With Multiple Islet Autoantibodies (DiAPREV-IT2) [ 142 ] Stage 1; identified through DiPiS, TEDDY or TrialNet; age 4–17; n=80 2 sc injections of Alum- GAD (Diamyd) or placebo 30 days apart, combined with vitamin D3 2000 iu/day, starting 30 days prior to first GAD or placebo dose Enrolling, estimated completion 2022 Teplizumab, anti- CD3/T cell depletion Teplizumab for Prevention of Type 1 Diabetes in Relatives “At-Risk.” [ 94 ] TID relatives; stage 2, identified through TrialNet Pathway to Prevention; age 8–45;n=71 Daily iv infusion of teplizumab or placebo for 2 weeks Enrollment completed, study outcome expected 2019 Golimumab (TNF-α blocker)/anti-inflammatory A Study to Evaluate SIMPONI (Golimumab) Therapy in Children, Adolescents and Young Adults With Pre-Symptomatic Type 1 Diabetes [ 73 ] Stage 2; age 6–21; n=30 Weekly weight based sc injection of golimumab or placebo for 26 weeks Enrolling, estimated completion 2021 Open in a separate window Selected immunotherapy studies in Stage 1 or Stage 2 TID

Techniques: Injection